Colorectal Cancer Peptide Vaccine PolyPEPI1018 for Colorectal Cancer

"Affirmative. Information from clinicaltrials.gov indicates that this research project is actively trying to gather participants, with the first post being made on January 10th 2022 and last updated on the same date. Specifically, 15 individuals are needed for a single trial site."

"Considering the limited safety and efficacy data, our team at Power has given Colorectal cancer Peptide Vaccine PolyPEPI1018 a score of 1 on their scale."

"According to clinicaltrials.gov, this medical trial is currently enrolling new participants and has been since January 10th 2022 when it was first posted. The study's information was most recently updated on the same date."

"Presently, 43 different clinical trials researching Colorectal cancer Peptide Vaccine PolyPEPI1018 are ongoing. 4 of the active studies have entered Phase 3 and all originate from Lakewood, New jersey; however, 527 sites around the world are running these tests."

"Since 2017, the research of Colorectal cancer Peptide Vaccine PolyPEPI1018 has continued to gain traction. The initial study was sponsored by Taiho Oncology and encompassed 56 participants. Upon successful completion of Phase 1 & 2 trials, 43 studies have sprung up in 235 cities and 28 countries worldwide."

"Patients diagnosed with ocular vaccinia infection, who have previously been administered oxaliplatin chemotherapy and anti-vegf treatment, can be aided using the Colorectal cancer Peptide Vaccine PolyPEPI1018."